{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T12:02:28Z","timestamp":1784721748692,"version":"3.55.0"},"reference-count":40,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Development of methods for adapting biological pathogens for the production of potentially important vaccines to ensure the epidemiological security of the Russian Federation","award":["FNZG-2026-0005"],"award-info":[{"award-number":["FNZG-2026-0005"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Objectives: Antiviral vaccines are usually created by inactivating viruses using physical or chemical methods. Inactivation of poliovirus with \u03b2-propiolactone (BPL) has advantages, including the absence of a requirement for long-term incubation with the inactivating agent, which minimizes the risk of negative effects of the potentially dangerous substance on the virus and reduces the duration of the inactivation process. Methods: BPL was applied at 0.2% (w\/v) concentration under two conditions: 4 \u00b0C for 24 h and 37 \u00b0C for 3 h. Inactivation completeness was confirmed on Vero cell culture, while immunogenicity was assessed in guinea pigs via neutralizing antibody test. Conclusions: Two variants of virus inactivation made it possible to obtain inactivated samples that retained their immunogenic properties. BPL-inactivated samples retained sufficient D-antigen levels and elicited neutralizing antibodies comparable to or exceeding those from formaldehyde-inactivated controls. The inactivation method at 37 \u00b0C provided faster inactivation, while at 4 \u00b0C it provided a smooth decrease in virus titer. These results confirm that \u03b2-propiolactone is a viable alternative to formaldehyde for the production of inactivated polio vaccine (IPV), providing rapid inactivation of the virus compared to inactivation with formaldehyde while maintaining immunogenicity, as confirmed by guinea pig control.<\/jats:p>","DOI":"10.3390\/vaccines14070642","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:17:52Z","timestamp":1784647072000},"page":"642","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inactivation of Wild Poliovirus with \u03b2-Propiolactone"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3200-763X","authenticated-orcid":false,"given":"Anastasia","family":"Kovpak","sequence":"first","affiliation":[{"name":"Chumakov FSC R&D IBP RAS (Institute of Poliomyelitis), Building 1, Village of the Institute of Poliomyelitis 8, Municipal District Filimonkovskiy, Moscow 108819, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Pashkov","sequence":"additional","affiliation":[{"name":"Chumakov FSC R&D IBP RAS (Institute of Poliomyelitis), Building 1, Village of the Institute of Poliomyelitis 8, Municipal District Filimonkovskiy, Moscow 108819, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariia","family":"Kostrova","sequence":"additional","affiliation":[{"name":"Chumakov FSC R&D IBP RAS (Institute of Poliomyelitis), Building 1, Village of the Institute of Poliomyelitis 8, Municipal District Filimonkovskiy, Moscow 108819, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1043-8869","authenticated-orcid":false,"given":"Kirill","family":"Nebesnyi","sequence":"additional","affiliation":[{"name":"Chumakov FSC R&D IBP RAS (Institute of Poliomyelitis), Building 1, Village of the Institute of Poliomyelitis 8, Municipal District Filimonkovskiy, Moscow 108819, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita","family":"Yakovlev","sequence":"additional","affiliation":[{"name":"Chumakov FSC R&D IBP RAS (Institute of Poliomyelitis), Building 1, Village of the Institute of Poliomyelitis 8, Municipal District Filimonkovskiy, Moscow 108819, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9568-0692","authenticated-orcid":false,"given":"Olga","family":"Polyakova","sequence":"additional","affiliation":[{"name":"Chumakov FSC R&D IBP RAS (Institute of Poliomyelitis), Building 1, Village of the Institute of Poliomyelitis 8, Municipal District Filimonkovskiy, Moscow 108819, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0638-3383","authenticated-orcid":false,"given":"Vladislav","family":"Vasilenko","sequence":"additional","affiliation":[{"name":"Chumakov FSC R&D IBP RAS (Institute of Poliomyelitis), Building 1, Village of the Institute of Poliomyelitis 8, Municipal District Filimonkovskiy, Moscow 108819, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lycheva","family":"Natalia","sequence":"additional","affiliation":[{"name":"Chumakov FSC R&D IBP RAS (Institute of Poliomyelitis), Building 1, Village of the Institute of Poliomyelitis 8, Municipal District Filimonkovskiy, Moscow 108819, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0995-7944","authenticated-orcid":false,"given":"Yury","family":"Ivin","sequence":"additional","affiliation":[{"name":"Chumakov FSC R&D IBP RAS (Institute of Poliomyelitis), Building 1, Village of the Institute of Poliomyelitis 8, Municipal District Filimonkovskiy, Moscow 108819, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5381-2393","authenticated-orcid":false,"given":"Anastasia","family":"Piniaeva","sequence":"additional","affiliation":[{"name":"Chumakov FSC R&D IBP RAS (Institute of Poliomyelitis), Building 1, Village of the Institute of Poliomyelitis 8, Municipal District Filimonkovskiy, Moscow 108819, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Siniugina","sequence":"additional","affiliation":[{"name":"Chumakov FSC R&D IBP RAS (Institute of Poliomyelitis), Building 1, Village of the Institute of Poliomyelitis 8, Municipal District Filimonkovskiy, Moscow 108819, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aydar","family":"Ishmukhametov","sequence":"additional","affiliation":[{"name":"Chumakov FSC R&D IBP RAS (Institute of Poliomyelitis), Building 1, Village of the Institute of Poliomyelitis 8, Municipal District Filimonkovskiy, Moscow 108819, Russia"},{"name":"Institute of Translational Medicine and Biotechnology, Sechenov Moscow State Medical University, Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"ref_1","first-page":"142","article-title":"Promising directions for improving vaccines for polio prevention","volume":"22","author":"Evreinova","year":"2022","journal-title":"Bioprep. Profil. Diagn. Lechenie"},{"key":"ref_2","unstructured":"(2020, July 03). GPEI-Polio Endgame Strategy. Available online: http:\/\/polioeradication.org\/who-we-are\/polio-endgamestrategy-2019-2023\/."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Abd-Elghaffar, A.A., Rashed, M.E., Ali, A.E., and Amin, M.A. (2020). In-Vitro Inactivation of Sabin-Polioviruses for Development of Safe and Effective Polio Vaccine. Vaccines, 8.","DOI":"10.3390\/vaccines8040601"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7939","DOI":"10.1038\/s41598-020-64531-1","article-title":"Complexity and ultrastructure of infectious extracellular vesicles from cells infected by non-enveloped virus","volume":"10","author":"Yang","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Piniaeva, A.N., and Ignatyev, G.M. (2021). Immunogenicity and Safety of Inactivated Sabin-Strain Polio Vaccine \u201cPoliovacSin\u201d: Clinical Trials Phase I and II. Vaccines, 9.","DOI":"10.3390\/vaccines9060565"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1099\/0022-1317-74-4-685","article-title":"Antigenic structure of poliovirus in inactivated vaccines","volume":"74","author":"Ferguson","year":"1993","journal-title":"J. General. Virol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Tobin, G.J., and Tobin, J.K. (2020). A novel gamma radiation-inactivated sabin-based polio vaccine. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0228006"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.vaccine.2019.01.086","article-title":"Inactivated or damaged? Comparing the effect of inactivation methods on influenza virions to optimize vaccine production","volume":"37","author":"Signorazzi","year":"2019","journal-title":"Vaccine"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/0006-291X(89)92234-1","article-title":"Stabilization of poliovirus against heat inactivation","volume":"159","author":"Dorval","year":"1989","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1089\/vim.2010.0028","article-title":"Immunogenicity and protective efficacy in mice and hamsters of a \u03b2-propiolactone inactivated whole virus SARS-CoV vaccine","volume":"23","author":"Roberts","year":"2010","journal-title":"Viral Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1089\/104454904323145272","article-title":"Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB\/c mice","volume":"23","author":"Tang","year":"2004","journal-title":"DNA Cell Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e2305","DOI":"10.1002\/rmv.2305","article-title":"Safety and potency of BIV1-CovIran inactivated vaccine candidate for SARS-CoV-2: A preclinical study","volume":"32","author":"Abdoli","year":"2022","journal-title":"Rev. Med. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.omtm.2021.08.005","article-title":"Immunological evaluation of an inactivated SARS-CoV-2 vaccine in rhesus macaques","volume":"23","author":"Chen","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.abc1932","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","volume":"369","author":"Gao","year":"2020","journal-title":"Science"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1080\/22221751.2021.1971569","article-title":"Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies","volume":"10","author":"Kozlovskaya","year":"2021","journal-title":"Emerg. Microbes Infect."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jama.2020.15543","article-title":"Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials","volume":"324","author":"Xia","year":"2020","journal-title":"JAMA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1021\/acs.chemrestox.9b00389","article-title":"Carcinogenesis of \u03b2-Propiolactone: A Computational Study","volume":"33","author":"Bren","year":"2020","journal-title":"Chem. Res. Toxicol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1006\/biol.1995.0034","article-title":"Inactivation of DNA by \u03b2-propiolactone","volume":"23","author":"Perrin","year":"1995","journal-title":"Biologicals"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"114733","DOI":"10.1016\/j.jviromet.2023.114733","article-title":"\u0392-Propiolactone (BPL)-inactivation of SARS-Co-V-2: In vitro validation with focus on saliva from COVID-19 patients for scent dog training","volume":"317","author":"Prajeeth","year":"2023","journal-title":"J. Virol. Methods"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"198555","DOI":"10.1016\/j.virusres.2021.198555","article-title":"Inactivation of SARS-CoV-2 by \u03b2-propiolactone causes aggregation of viral particles and loss of antigenic potential","volume":"305","author":"Gupta","year":"2021","journal-title":"Virus Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0092-1157(86)90028-4","article-title":"Inactivation of poliovirus with beta-propiolactone","volume":"14","author":"Jiang","year":"1986","journal-title":"J. Biol. Stand."},{"key":"ref_22","unstructured":"(2026, July 17). Recommendation of the Board of the Eurasian Economic Commission No. 33 Dated November 14, 2023 \u201cOn Guidelines for Working with Laboratory (Experimental) Animals During Preclinical (Non-Clinical) Studies\u201d. Available online: https:\/\/www.alta.ru\/tamdoc\/23rk0033\/."},{"key":"ref_23","unstructured":"(2026, July 17). Directive 2010\/63\/EU of the European Parliament and of the Council of the European Union on the Protection of Animals Used for Scientific Purposes of September 22, 2010. Available online: https:\/\/eur-lex.europa.eu\/eli\/dir\/2010\/63\/oj\/eng."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bsheal.2021.12.008","article-title":"Immunogenicity and protective efficacy of an inactivated SFTS vaccine candidate in mice","volume":"4","author":"Li","year":"2022","journal-title":"Biosaf. Health"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"104878","DOI":"10.1016\/j.psj.2025.104878","article-title":"Assessing the effect of beta-propiolactone inactivation on the antigenicity and immunogenicity of cluster 2.1 duck Tembusu virus","volume":"104","author":"Rungprasert","year":"2025","journal-title":"Poult. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"110217","DOI":"10.1016\/j.fsi.2025.110217","article-title":"Comparative analysis of immunogenicity for viral hemorrhagic septicemia virus (VHSV) vaccines inactivated by different methods","volume":"160","author":"Kim","year":"2025","journal-title":"Fish. Shellfish Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1016\/j.vaccine.2007.01.086","article-title":"A microcarrier cell culture process for propagating rabies virus in Vero cells grown in a stirred bioreactor under fully animal component free conditions","volume":"25","author":"Rourou","year":"2007","journal-title":"Vaccine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1139\/m57-095","article-title":"The use of beta-propiolactone for the preparation of virus vaccines. I. Selection of reaction conditions","volume":"3","author":"Polley","year":"1957","journal-title":"Can. J. Microbiol."},{"key":"ref_29","first-page":"84","article-title":"Selection of Sorbent for Poliovirus Vaccine Strain Concentrate Purification by Gel Filtration","volume":"N37","author":"Piniaeva","year":"2021","journal-title":"Biotekhnologiya"},{"key":"ref_30","first-page":"107","article-title":"Application of ion-exchange chromatography in the development of technology for inactivated polio vaccine production","volume":"21","author":"Pinyaeva","year":"2022","journal-title":"Epidemiol. Vaktsinoprofilaktika"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Zyrina, A., and Shishova, A. (2025). Generation of Polyclonal Antibodies Against Sabin Poliovirus D- and H-Antigens and Their Application in ELISA. Vaccines, 13.","DOI":"10.3390\/vaccines13101022"},{"key":"ref_32","unstructured":"WHO (2026, January 28). Guidelines for WHO\/EPI Collaborative Studies on Poliomyelitis: Standard Procedure for Determining Immunity to Poliovirus Using the Microneutralization Test. Available online: https:\/\/apps.who.int\/iris\/."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"253","DOI":"10.18097\/pbmc20236905253","article-title":"Perspectives for the creation of a new type of vaccine preparations based on pseudovirus particles using polio vaccine as an example","volume":"69","author":"Zhdanov","year":"2023","journal-title":"Biomeditsinskaia Khimiia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1073\/pnas.051598298","article-title":"Viral capsid mobility: A dynamic conduit for inactivation","volume":"98","author":"Broo","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","first-page":"209","article-title":"Beta-Propiolactone: Viral inactivation in vaccines and plasma products","volume":"54","author":"Lawrence","year":"2000","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0264-410X(91)90057-D","article-title":"Principles of selective inactivation of viral genome. V. Rational selection of conditions for inactivation of the viral suspension infectivity to a given extent by the action of beta-propiolactone","volume":"9","author":"Budowsky","year":"1991","journal-title":"Vaccine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1021\/bi00836a020","article-title":"Chemical modification of viral ribonucleic acid","volume":"8","author":"Singer","year":"1969","journal-title":"Biochemistry"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Zhdanov, D.D., and Shishparenok, A.N. (2025). Degradation of Poliovirus Sabin 2 Genome After Electron Beam Irradiation. Vaccines, 13.","DOI":"10.3390\/vaccines13080824"},{"key":"ref_39","unstructured":"Plotkin, S.A., and Orenstein, W. (2012). Vaccines, Elsevier. [6th ed.]."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1016\/j.vaccine.2023.01.031","article-title":"Antigenic diversity of type 1 polioviruses and its implications for the efficacy of polio vaccines","volume":"41","author":"Kouiavskaia","year":"2023","journal-title":"Vaccine"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/7\/642\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:19:15Z","timestamp":1784719155000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/7\/642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":40,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["vaccines14070642"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14070642","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]}}}